A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL).
Martin Gutierrez
No relevant relationships to disclose
Andre Goy
No relevant relationships to disclose
John C. Byrd
Research Funding - Karyopharm Therapeutics
Joseph M. Flynn
No relevant relationships to disclose
Morten Sorensen
Research Funding - Karyopharm Therapeutics
Peter Brown
No relevant relationships to disclose
Nashat Y. Gabrail
No relevant relationships to disclose
Michael Savona
No relevant relationships to disclose
Ian Flinn
No relevant relationships to disclose
Rachid C. Baz
No relevant relationships to disclose
Bijal D. Shah
No relevant relationships to disclose
Richard M. Stone
No relevant relationships to disclose
Eric Jacobsen
No relevant relationships to disclose
Vishal Kukreti
No relevant relationships to disclose
Roger E. Tiedemann
No relevant relationships to disclose
Tami Rashal
Consultant or Advisory Role - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Mansoor Raza Mirza
Consultant or Advisory Role - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Sharon Shacham
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Michael Kauffman
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
John Kuruvilla
No relevant relationships to disclose